5Arca R,lbarra J,Lerzo G,et al.Gemcitabine (GEM) +oxaliplatin (OX) in patients (pts) with stage Ⅲ/Ⅳ ovarian cancer following 3 cycles of carboplatin (CB) + paclitaxel (PAC):preliminary report of a phase Ⅱ study:5111.J Clin Oncol,2004,22:476. 被引量：1
6Maenpaa JU,Grénman SE,Jalkanen JT,et al.Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer:a phase Ⅱ study.Gynecol Oncol,2006,101:114-119. 被引量：1
7Pfisterer J,Weber B,Reuss A,et al.Randomized phase Ⅲ trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer:a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.J Nail Cancer Inst,2006,98:1036-1045. 被引量：1
8Hu J,Khanna V,Jones MM,et al.Genomic imbalances in ovarian borderline serous and mucinous tumors.Cancer Genet Cytogenet,2002,139:18-23. 被引量：1
9Kuo KT,Guan B,Feng Y,et al.Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.Cancer Res,2009,69:4036-4042. 被引量：1
10Alexandre J,Ray-Coquard I,Selle F,et al.Mucinous advanced epithelial ovarian carcinoma:clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience.Ann Oncol,2010,21:2377-2381. 被引量：1
3Gadducci A, Cosio S, Zola P, et al. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer, 2007,17:21-31. 被引量：1
4Cheung VG, Conlin LK, Weber TM, et al. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet ,2003,33:422-425. 被引量：1
5Tuxen MK, Soletormos G, Petersen PH, et al. Assessment of biological variation and analytical imprecision of CA125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol, 1999,74 : 12-22. 被引量：1
6Berchuck A, O1t GJ, Soisson AP, et al. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol, 1990,162:883-888. 被引量：1
7Tangjitgamol S, See HT, Manusirivithaya S, et al. Third-line chemotherapy in platinum- and paelitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. Int J Gynecol Caneer,2004 ,14 :804-814. 被引量：1
8Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA125 : a North Thames Ovary Group study. Ann Oncol, 1996, 7:361-364. 被引量：1
9Fioretti P, Gadducci A, Ferdeghini M, et al. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol, 1992,44 : 155-160. 被引量：1
10Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 2005,99:267-277. 被引量：1
